Multiple Sclerosis Clinical Trial

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Summary

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant has diagnosis of relapsing remitting multiple sclerosis (RRMS) or secondary-progressive multiple sclerosis (SPMS) with relapses within the past 24 months.
Participant has cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with multiple sclerosis (MS).
Participant has evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test.

Exclusion Criteria:

- Participants must not have experienced or be recovering from a clinical MS relapse within 6 months of Screening.

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

208

Study ID:

NCT03737851

Recruitment Status:

Completed

Sponsor:

AbbVie

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 49 Locations for this study

See Locations Near You

University of Alabama at Birmingham - Main /ID# 204618
Birmingham Alabama, 35233, United States
St. Josephs Hospital and Med Center /ID# 204197
Phoenix Arizona, 85013, United States
Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249
Berkeley California, 94705, United States
The Research Center of Southern California /ID# 204269
Carlsbad California, 92011, United States
Vladimir Royter MD /ID# 204392
Hanford California, 93230, United States
UC Irvine Health /ID# 205728
Irvine California, 92697, United States
Stanford MS Center /ID# 204283
Palo Alto California, 94304, United States
UC Davis Health-Neurological Surgery /ID# 204188
Sacramento California, 95817, United States
UCSF School of Medicine - Neurology /ID# 204251
San Francisco California, 94143, United States
University of Colorado School of Medicine /ID# 204250
Aurora Colorado, 80045, United States
Advanced Neurosciences Research, LLC /ID# 204289
Fort Collins Colorado, 80528, United States
The University of Chicago Medical Center /ID# 205319
Chicago Illinois, 60637, United States
Indiana Univ School Medicine /ID# 204891
Indianapolis Indiana, 46202, United States
Rowe Neurology Institute /ID# 204391
Lenexa Kansas, 66214, United States
The NeuroMedical Center /ID# 204253
Baton Rouge Louisiana, 70810, United States
Ochsner Medical Center /ID# 204189
New Orleans Louisiana, 70121, United States
Duplicate_Parexel International /ID# 204273
Baltimore Maryland, 21225, United States
International Neurorehabilitation Institute /ID# 213332
Lutherville Maryland, 21093, United States
Pediatric Endocrine Associates /ID# 204279
Boston Massachusetts, 02114, United States
Michigan Institute for Neurological Disorders (MIND) /ID# 204194
Farmington Hills Michigan, 48334, United States
Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206328
Owosso Michigan, 48867, United States
Ridgeview Specialty Clinic Chaska - Neurology /ID# 204383
Chaska Minnesota, 55318, United States
Washington University-School of Medicine /ID# 204388
Saint Louis Missouri, 63110, United States
The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205433
Saint Louis Missouri, 63131, United States
Cleveland Clinic Lou Ruvo Cent /ID# 204745
Las Vegas Nevada, 89106, United States
Oklahoma Med Res. Foundation /ID# 204389
Oklahoma City Oklahoma, 73104, United States
Providence Neurological Specialties - West /ID# 204248
Portland Oregon, 97225, United States
Thomas Jefferson University /ID# 204281
Philadelphia Pennsylvania, 19107, United States
Advanced Neurosciences Institute /ID# 204557
Franklin Tennessee, 37064, United States
KCA Neurology - Franklin /ID# 204208
Franklin Tennessee, 37067, United States
Tri-State Mountain Neurology /ID# 204252
Johnson City Tennessee, 37604, United States
Neurology Consultants of Dallas - LBJ Fwy /ID# 204398
Dallas Texas, 75243, United States
UT HSC Multiple Sclerosis Research Group - Houston /ID# 206418
Houston Texas, 77030, United States
Dr. Bhupesh Dihenia, MD, PA /ID# 207839
Lubbock Texas, 79410, United States
Central Texas Neurology Consul /ID# 204268
Round Rock Texas, 78681, United States
Integrated Neurology Services, PLLC /ID# 204261
Alexandria Virginia, 22310, United States
Evergreen Neuroscience Institute /ID# 204203
Kirkland Washington, 98034, United States
Virginia Mason Medical Center /ID# 205440
Seattle Washington, 98101, United States
Swedish MS Center /ID# 204198
Seattle Washington, 98122, United States
University of Washington Medicine MS Center /ID# 205852
Seattle Washington, 98133, United States
West Virginia Univ School Med /ID# 204292
Morgantown West Virginia, 26506, United States
Froedtert Memorial Lutheran Hospital /ID# 204202
Milwaukee Wisconsin, 53226, United States
University of British Columbia - MS & NMO Clinical Trials Group, Djavad Mowafagh /ID# 204841
Vancouver British Columbia, V6T 1, Canada
Duplicate_London Health Sciences Centre - University Hospital /ID# 204848
London Ontario, N6A 5, Canada
Ottawa Hospital Research Institute /ID# 204842
Ottawa Ontario, K1H 8, Canada
Unity Health Toronto - St. Michael's Hospital /ID# 206214
Toronto Ontario, M5B 1, Canada
Recherche Sepmus Inc. /ID# 212851
Greenfield Park Quebec, J4V 2, Canada
Centre Hospitalier de l'Universite de Montreal - CRCHUM /ID# 204844
Montreal Quebec, H2X 0, Canada
Montreal Neurological Institut /ID# 204843
Montreal Quebec, H3A 2, Canada

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

208

Study ID:

NCT03737851

Recruitment Status:

Completed

Sponsor:


AbbVie

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.